Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX59 (DDX59) is an enzyme of the DEAD-box helicase family, characterized by a conserved Asp-Glu-Ala-Asp (DEAD) motif. Like other DEAD-box helicases, DDX59 is predicted to use the energy of ATP hydrolysis to unwind RNA duplexes, thus regulating various aspects of RNA metabolism including RNA processing, splicing, transport, translation, and degradation[2][3][4][7]. DDX59 is found in the cytoplasm and nucleus and is associated with orofaciodigital syndrome V[7]. While specific small-molecule modulators or approved drugs targeting DDX59 are not documented, DEAD-box helicases as a family are considered putative therapeutic targets due to their roles in cancer and other diseases[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX59 (DDX59).